European viper snake venom antiserum
Brand names: ViperaTAb, Viperfav
European viper venom antiserum is an antivenom used to treat significant envenoming by the European adder and related vipers.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It contains antibody fragments that bind and neutralise circulating viper venom components, limiting their local and systemic toxic effects.
Prescribing in practice
- Reserve for patients with signs of significant systemic or progressive local envenoming, and be prepared to treat anaphylaxis, as serious hypersensitivity reactions can occur.
- Administer in a setting with full resuscitation facilities and adrenaline immediately available.
- Discuss management with the National Poisons Information Service, as further doses may be required if envenoming progresses.
Monitoring
Monitor closely for hypersensitivity reactions during administration and reassess local and systemic envenoming features afterwards.
Counselling the patient
- Explain that this antivenom neutralises adder venom and is reserved for serious bites.
- Warn about the possibility of an allergic reaction during or after treatment.
- Advise reporting rash, breathlessness or feeling faint immediately.
Evidence & guidelines
Antivenom is the specific treatment for significant viper envenoming in the UK, with use and supply coordinated through the National Poisons Information Service.
Reference: TOXBASE; NPIS; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Difficult Airway Algorithm (DAS) · DAS 2015; Royal College of Anaesthetists
- Major Haemorrhage Protocol · NICE NG24; UK MHP guidelines
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines